CellSearch System cleared for monitoring metastatic breast cancer

December 15, 2006

WARREN, N.J., Dec. 15, 2006 - Veridex, a Johnson & Johnson company, today announced that the U.S. Food and Drug Administration (FDA) has granted an expanded clearance for the CellSearch™ System to be used as an aid in the monitoring of metastatic breast cancer.

The CellSearch™ System identifies and counts circulating tumor cells (CTCs) in a blood sample to predict progression-free survival and overall survival in patients with metastatic breast cancer earlier than the current standard of care. The results of serial testing for CTCs with the CellSearch™ System, in conjunction with other clinical methods for monitoring breast cancer, can help inform physicians' treatment decisions.

"The clearance of the CellSearch™ System as a routine monitoring diagnostic tool validates its efficacy as a critical part of the resources used to manage patients with metastatic breast cancer," said Mark Myslinski, General Manager, Veridex LLC. "With the CellSearch™ test, oncologists can clearly and consistently monitor the number of circulating tumor cells present in a patient's blood, an indication of disease progression."

The CellSearch™ System is the first diagnostic test to automate the detection and enumeration of CTCs, cancer cells that detach from solid tumors and enter the blood stream, and is the standard in a new class of diagnostic tools. The presence and number of CTCs in the blood provides valuable information to physicians for developing individual management programs for patients with metastatic breast cancer. The system's sensitivity, specificity and reproducibility allow for more rapid observation of CTCs as early as the first cycle of treatment helping to evaluate disease progression sooner.

According to the American Cancer Society, breast cancer claims approximately 40,000 lives each year, the vast majority of which are a result of recurrent metastatic disease. Metastatic breast cancer occurs when tumor cells spread to other locations in the body and grow. Although there are many options for the treatment of metastatic breast cancer, oncologists often have to wait several months before they can determine if a specific treatment is beneficial to the patient. The CellSearch™ System helps physicians to predict if treatment is effective at any time during therapy through its ability to locate one circulating tumor cell in the 40 billion cells contained in a 7.5 ml sample of blood - an achievement no other diagnostic approach has been able to accomplish.

The CellSearchTM System was cleared by the FDA in January 2004 as a diagnostic tool for identifying and counting CTCs in a blood sample to predict progression-free survival and overall survival in patients with metastatic breast cancer.
About Veridex

Veridex, LLC, a Johnson & Johnson company, develops cancer diagnostic products that will enable earlier disease detection as well as more accurate staging, monitoring and therapeutic selection. The company is initially developing two complementary product lines: CellSearch™ assays that identify, enumerate and characterize circulating tumor cells directly from whole blood; and GeneSearch™ assays that use molecular technology to diagnose, stage and more accurately characterize tumors. www.veridex.com

Veridex, LLC

Related Metastatic Breast Cancer Articles from Brightsurf:

New research supports clinical utility of CTC count for metastatic breast cancer
Menarini Silicon Biosystems, the pioneer of liquid biopsy technology, today announced the publication of a research study providing support for the reliability of using circulating tumor cell (CTC) count to guide frontline therapy choice for patients with estrogen receptor-positive (ER+), HER2-negative (HER2) metastatic breast cancer.

Surgery and radiation do not extend survival in newly diagnosed metastatic breast cancer
Women who present with a new diagnosis of breast cancer that is already in an advanced stage (stage IV) face questions about having surgery and radiation to the tumor in the breast (local therapy).

Novel biomarkers predict benefit with immunotherapy in metastatic breast cancer
Two novel biomarkers have been found to correlate with improved outcomes with immunotherapy in metastatic breast cancer and may help to identify the patients most likely to benefit from this treatment, according to exploratory studies reported at the ESMO Breast Cancer Virtual Meeting 2020.

Activation of a distinct genetic pathway can slow the progress of metastatic breast cancer
Activation of the BMP4 signalling pathway presents a new therapeutic strategy to combat metastatic breast cancer, a disease that has shown no reduction in patient mortality over the past 20 years.

Hyperactive FOXA1 reprograms endocrine-resistant breast cancer to become metastatic
A team led by researchers at Baylor College of Medicine and Harvard Medical School has unveiled a novel mechanism that helps explain how endocrine-resistant breast cancer acquires metastatic behavior, opening the possibility of new therapeutic strategies.

Attacking metastatic breast cancer with sound
Drugs can be safely delivered to cancerous lymph nodes via the lymphatic system and then released inside the nodes using sound waves.

Oncolytics Biotech® and PrECOG announce study in metastatic breast cancer
Oncolytics Biotech® Inc., developing pelareorep, an intravenously delivered immuno-oncolytic virus, and PrECOG LLC, today announced the BRACELET-1 (PrE0113) study, to evaluate the ability of pelareorep to make tumors immunologically visible to checkpoint inhibitors.

Study supports germline testing for all metastatic breast cancer patients
Genetic testing for all metastatic breast cancer patients may be an optimal strategy for identifying additional patients with increased risk as well as response to targeted therapies, according to research published in JAMA Oncology.

Adding targeted therapy to treatment extends lives of those with metastatic breast cancer
A UCLA-led study has found that using a drug called ribociclib in combination with a common hormone therapy may help premenopausal women with the most common type of breast cancer live longer than if they only receive the hormone therapy.

New 'smart drug' shows promise for metastatic triple-negative breast cancer
A clinical trial at NewYork-Presbyterian/Columbia and other centers found that patients responded to a new 'smart drug' for women with an aggressive form of breast cancer.

Read More: Metastatic Breast Cancer News and Metastatic Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.